XML 23 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies (Details Narrative) (USD $)
1 Months Ended
Aug. 31, 2012
Mar. 20, 2015
Feb. 02, 2015
Apr. 12, 2013
Commitments and Contingencies Disclosure [Abstract]        
Cancellation of company common shares held by Plaintiff       103,030,303BMSN_CancellationOfCompanyCommonSharesHeldByPlaintiff
Satisfaction of convertible indebtedness held by Plaintiff       $ 17,000BMSN_SatisfactionOfConvertibleIndebtednessHeldPlaintiff
Limitation on conversion of outstanding common stock       9.99%BMSN_LimitationOnConversionOfOutstandingCommonStock
Convertible Note to plaintiff, payable April 1, 2016     300,000us-gaap_ConvertibleDebt  
Payment for consideration of note conversion     52,500BMSN_PaymentForConsiderationOfNoteConversion  
Conversion discount rate     55.00%BMSN_ConversionDiscountRate  
Settlement with PRI Parties, payment per month 1,000us-gaap_PaymentsForLegalSettlements      
Regen Biopharma monthly sublease fee to HBRI   400us-gaap_ContractualObligation    
Regen Biopharma monthly research agreement fee   $ 2,700BMSN_ContractualObligation1